Past Clinical Trials

PASS

Genzyme, A Sanofi Company: A Prospective, Multicenter Observational, Post-Authorization Safety Study to Evaluate the Long Term Safety Profile of LEMTRADA (alemtuzumab) Treatment in Patients With Relapsing Forms of Multiple Sclerosis. Closed to enrollment.

Vaccinex: A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single=Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous XXXX in Patients with Multiple Sclerosis. Closed to enrollment.

CHORDS

Genentech: An Open-Label Study To Evaluate The Effectiveness And Safety Of XXXX in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had A Suboptimal Response To An Adequate Course Of Disease-Modifying Treatment. Closed to enrollment.

VELOCE

Roche: A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study To Evaluate the Effects of XXXX on Immune Responses With Relapsing Forms of Multiple Sclerosis. Closed to enrollment.

LEM-COG

Genzyme, A Sanofi Company: A Prospective 24-Month Observational Study to Evaluate Neurocognitive Function and Safety in Patients with Relapsing Multiple Sclerosis Who Are Initiating LEMTRADA Treatment in Routine Clinical Practice. Closed to enrollment.

PRO-ACT

Genzyme, A Sanofi Company: A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA Treatment in Patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modifying Therapy. Closed to enrollment.

LILAC

Pfizer: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center Trial of XXXX As Adjunctive Therapy in Pediatric and Adult Subjects with Primary Generalized Tonic-Clonic Seizures. Closed to enrollment.

ASCLEPIOS

Novartis: A Randomized, Double-Blind, Double Dummy, Parallel-Group Study Comparing the Efficacy and Safety of XXXX versus XXXX in Patients with Relapsing Multiple Sclerosis. Closed to enrollment.

EVOLVE

Alkermes: A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of XXXX and XXXX. Closed to enrollment.

PREFER MS

Novartis: A 12-Month, Prospective, Randomized, active-controlled, open-label study to evaluate patient retention of XXXX vs. approved first-line disease modifying therapies in adults with relapsing remitting multiple sclerosis. Closed to enrollment.

ASSESS

Novartis: A 12-month, randomized, rater and dose-blinded study to compare the efficacy and safety of XXXX 0.25mg and 0.5mg administered orally once daily with XXXX 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis. Closed to enrollment.

EMPIRE

Genzyme, A Sanofi Company: A Phase 2a/2b double-blind, randomized, placebo-controlled study assessing efficacy, safety, and dose-response of XXXX in patients with relapsing-remitting multiple sclerosis (RRMS). Closed to enrollment.

TRANSITION

Novartis: A multicenter, retrospective, observational study evaluating real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who transition from XXXX to Gilenya.

ENHANCE

Biogen Idec: A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release XXXX 10mg, Administered Twice Daily in Subjects with Multiple Sclerosis. Closed to enrollment.

CAMMS

Genzyme, A Sanofi Company: An Extension Protocol for the Multiple Sclerosis Patients Who Participated in Genzyme Sponsored Studies of XXXX. Closed to enrollment.

TOPAZ

Genzyme, A Sanofi Company: A long-term follow-up study for Multiple Sclerosis patients who have completed the XXXX Extension Study. Closed to enrollment.

CONFIDENCE

Teva: A Multinational, Multi-center, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous Injections of XXXX 40mg/mL Three Times a Week Compared to 20mg/mL Daily. Closed to enrollment.

REDEFINE

EMD Serono: A phase IV, randomized, prospective, US-based, multi-center, cross-over study evaluating subject's ease-of-use with XXX, XXX, and XXX autoinjectors in subjects with relapse remitting multiple sclerosis (RRMS) treated with XXXX 44mcg subcutaneously three times a week. Closed to enrollment.

TERIKIDS

Genzyme, A Sanofi Company: A two year, multi-center, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability, and pharmacokinetics of XXXX administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis. Closed to enrollment.

PASSAGE

Novartis: Long-term, prospective, observational, multinational, parallel-cohort study monitoring the safety in patients with MS, newly started with XXX once daily or treated with another approved disease-modifying therapy. Closed to enrollment.

IVSS

Genzyme, A Sanofi Company:A prospective observational cohort study in adult patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA (alemtuzumab) infusions of the first treatment course. Closed to enrollment.